The Swiss pharmaceutical company, Novartis, have announced that will be discontinuing the development of the lung cancer treatment, Vademezan.
The decision was taken once interim results from a Phase III trial shown the drug was not likely to meet it’s primary objective of extending overall survival when used in comination with chemotherapy in the treatment of patients will non-small cell lung cancer.
Novartis have announced that the resources will now be reallocated to other compounds in it’s oncology pipeline.
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.